Lenomorelin (Anamorelin)

An orally active ghrelin receptor agonist developed primarily for cancer-related anorexia and cachexia. It stimulates appetite and increases GH secretion through selective ghrelin mimicry, and has received regulatory approval in Japan.

• Selectively agonizes the GHS-R1a (ghrelin) receptor to stimulate GH release and appetite
• Activates hypothalamic feeding centers through NPY/AgRP neurons
• Promotes positive nitrogen balance and lean mass accretion via GH/IGF-1 axis activation

• Significant cardiac conduction disorders (QT prolongation risk)
• Pregnancy or breastfeeding
• Uncontrolled diabetes
• Hepatic impairment

Store at room temperature (15–25°C (59–77°F)) in original packaging. Protect from moisture and light.

Anamorelin completed multiple Phase III trials (ROMANA 1, 2, and 3) demonstrating significant increases in lean body mass and body weight in patients with non-small cell lung cancer cachexia. It was approved in Japan in 2021 under the brand name Adlumiz. FDA approval was not pursued after the EMA declined authorization citing improvements in lean mass but insufficient evidence for functional improvement.